(firstQuint)This Study is Being Conducted to Evaluate the Safety, Tolerability, and Efficacy of KD025 Administered Orally for 16 Weeks to Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy or Phototherapy.

.

 This study will be performed in adult male and female subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.

 Study drug will be orally administered in a double-blind fashion for 16 weeks in order to evaluate efficacy through 16 weeks of treatment.

 Approximately 150 subjects will be randomly assigned to 1 of 5 dose cohorts: - 200 mg KD025 once daily (QD) - 200 mg KD025 BID - 400 mg KD025 QD - 600 mg/day KD025 (administered as 400 mg in the morning and 200 mg in the evening) - Placebo BID.

 This Study is Being Conducted to Evaluate the Safety, Tolerability, and Efficacy of KD025 Administered Orally for 16 Weeks to Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy or Phototherapy.

@highlight

This study is being conducted to evaluate the safety, tolerability, and efficacy of KD025 in adult subjects with moderate to severe chronic plaque psoriasis.

